Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA FE 1 20 versus TRI SPRINTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA FE 1 20 versus TRI SPRINTEC.
AUROVELA FE 1/20 vs TRI-SPRINTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. Inhibits ovulation by suppressing gonadotropin release (FSH, LH). Increases viscosity of cervical mucus, reducing sperm penetration. Alters endometrial lining to reduce implantation likelihood.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
One tablet (1 mg norethindrone acetate, 20 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by one iron tablet (75 mg ferrous fumarate) orally once daily for 7 days.
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
None Documented
None Documented
Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours (with interindividual variability).
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Renal: ~50-60% as metabolites; fecal: ~40-50% as metabolites; biliary excretion contributes to fecal elimination.
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive